Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Xetra  >  Bayer AG    BAYN


News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Sprint Bioscience : enters into collaboration with Bayer HealthCare on tumor metabolism program

07/29/2015 | 02:01pm US/Eastern

(GlobeNewswire) - Sprint Bioscience AB (publ) (Sprint Bioscience) and Bayer HealthCare (Bayer)

have entered into a collaboration and license agreement for the research,

development, and commercialization of oncological drug candidates. Under the

agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting

tumor metabolism to Bayer. Subsequently, Bayer will have full control over

further development and worldwide commercialization rights for potential cancer

therapeutics and diagnostics.

– “We are very happy to have entered into this agreement for one of our tumor

metabolism projects. We are convinced that Bayer is a perfect partner to further

develop this program. This agreement also gives us the opportunity to further

invest in the expansion of our portfolio within the area of tumor metabolism,”

said Dr Anders Åberg, CEO of Sprint Bioscience.

“Bayer is committed to translating the findings of cancer research into

effective therapies to improve the quality of life of patients. Addressing the

metabolism of cancer cells is a promising approach in oncology and one of our

focus areas in cancer research at Bayer,” said Professor Andreas Busch, Head of

Global Drug Discovery and member of the Executive Committee of Bayer HealthCare.

“We are looking forward to expanding our portfolio in this area through the

agreement with Sprint Bioscience. This early research program has the potential

to lead to new treatment options for cancer patients.”

As a result of a tumor's uncontrolled growth, cancer cells exhibit an altered

metabolism (tumor metabolism) and thereby are often resistant to conventional

radiation- and chemotherapy. Sprint Bioscience has developed molecules

inhibiting a novel metabolic target, which is vital for cancer cell survival.

Such inhibitors can potentially lead to effective new treatments by selectively

affecting cancer cells.

Sprint Bioscience is eligible to receive up to approximately 190 Million Euro in

potential preclinical, clinical and net sales based milestone payments,

including an upfront payment from Bayer upon signing of the agreement.

Furthermore, Sprint Bioscience is also eligible to receive royalties on

worldwide net sales of any resulting products under the collaboration.

About Sprint Bioscience

Sprint Bioscience AB (publ) is part of the new Swedish pharmaceutical industry.

The company has the goal to develop drug candidates for the global

pharmaceutical market within the field of oncology in a more time- and resource

-efficient manner. Sprint Bioscience is situated in Stockholm, Sweden. Sprint

Bioscience share is listed on NASDAQ First North and traded under the name


Additional information is available on the company website;


Certified Advisor is Redeye, www.redeye.se.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of

health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup

of Bayer AG with annual sales of around EUR 20.0 billion (2014), is one of the

world’s leading, innovative companies in the healthcare and medical products

industry and is based in Leverkusen, Germany. The company combines the global

activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals

divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and

market products that will improve human and animal health worldwide. Bayer

HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is

represented in more than 100 countries. More information is available at


For further information, please contact:

Anders Åberg, CEO, Sprint Bioscience

Tel: +46-8-411 44 55

E-Mail: anders.aberg@sprintbioscience.com

Sprint Bioscience AB (publ) is required to publish this information pursuant to

the Securities Markets Act and/or the Act on trading in financial instruments.

The information was submitted for publication on July 28, 2015 at 8:30 (CEST).

Sprint Bioscience ? Teknikringen 38A ?114 28 Stockholm ? Sweden ? 46-(0)8-411 44

55 ?info@sprintbioscience.com

For the original version on GlobeNewswire visit: http://globenewswire.com/news-release/2015/07/28/755423/0/en/Sprint-Bioscience-enters-into-collaboration-with-Bayer-HealthCare-on-tumor-metabolism-program.html

(c) 2015 Al Sidra Media LLC Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

React to this article
Latest news on BAYER AG
07/29 SPRINT BIOSCIENCE : enters into collaboration with Bayer HealthCare on tumor met..
07/29 SPRINT BIOSCIENCE : Bayer HealthCare Enters Into Collaboration With Sprint Biosc..
07/29DJBayer Profit Rises on Healthy Currency Effects
07/29DJBayer Sees Benefits of Currency Effects With 21% Rise in 2Q Profit -- Update
07/29 BAYER : significantly improves earnings
07/29DJBayer Sees Benefits of Currency Effects With 21% Rise in 2Q Profit
07/28 GLENMARK PHARMACEUTICALS : slips 2% on negative US Court ruling
07/28 BAYER : Offering integrated solutions and driving partnerships to promote sustai..
07/28 BAYER : Not intended for U.S. and UK Media -- Bayer HealthCare Enters Into Colla..
07/28 SPRINT BIOSCIENCE : enters into collaboration with Bayer HealthCare on tumor met..
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Income Statement Evolution
More Financials